Results 161 to 170 of about 80,394 (203)

Prevalence of Multidrug-Resistant Tuberculosis and Its Association With Previous Treatment History in Adults. [PDF]

Cureus
Ahmad Mughal M, Imran A, Khan HU, Farooq M, Ikram A, Arshad F, Ashraf R, Khatoon F.   +7 more
europepmc   +1 more source

Latent Profile Analysis and Influencing Factors of Medication-Related Burden in Multidrug-Resistant Tuberculosis Patients in Chengdu, China. [PDF]

Patient Prefer Adherence
Li Y, Yu Q, Yao R, Yang X, Wan B, Zhao X, Hu Y, Zhou Y, Dai L, Liu X, Xie E, Huang F, Xie F, Guo Z.   +13 more
europepmc   +1 more source

A Prospective Cohort Study on the Usage, Safety, and Efficacy of Delamanid in Patients With Pulmonary Multidrug-Resistant Tuberculosis in South Korea. [PDF]

Open Forum Infect Dis
Mok J, Seo H, Cho Y, Lee T, Kim SH, Park HK, Oh JY, Shim TS.   +7 more
europepmc   +1 more source

Real-world safety profile of novel anti-multidrug-resistant tuberculosis drugs: a disproportionality analysis based on the FAERS database. [PDF]

BMJ Open
Zhao L, Zeng L, Qian Y, Zhao W, Xie R.
europepmc   +1 more source

Evaluating the cost-effectiveness of levofloxacin therapy for household contacts of multidrug-resistant tuberculosis in Vietnam. [PDF]

Lancet Reg Health West Pac
Hasan T, Thu Anh N, Binh Hoa N, Viet Nhung N, Yapa HM, Graham SM, Marais BJ, Marks GB, Lung T, Fox GJ.   +9 more
europepmc   +1 more source

Secondary metabolites from <i>Lobaria pulmonaria</i> (L.) Hoffm. target key metabolic enzymes: a novel strategy against multidrug-resistant tuberculosis. [PDF]

RSC Adv
Nguyen HT, Badavath VN, Maji S, Polimati H, Okello E, Bunce RA, Thuan NH, Nuzul Hakimi Wan Salleh WM, Tatipamula VB.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Multidrug-resistant tuberculosis

Nature Reviews Disease Primers
Tuberculosis (TB) remains the foremost cause of death by an infectious disease globally. Multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB; resistance to rifampicin and isoniazid, or rifampicin alone) is a burgeoning public health challenge in several parts of the world, and especially Eastern Europe, Russia, Asia and sub-Saharan Africa.
Keertan Dheda, Fuad Mirzayev, Daniela Maria Cirillo, Zarir Udwadia, Kelly E. Dooley, Kwok-Chiu Chang, Shaheed Vally Omar, Anja Reuter, Tahlia Perumal, C. Robert Horsburgh, Megan Murray, Christoph Lange   +11 more
exaly   +6 more sources

Multidrug resistant cervical tuberculosis

American Journal of Otolaryngology, 1999
Tuberculosis (TB) remains a global health problem, with an annual incidence of 8 to 10 million cases and the death of 3 million people year1y.l Despite the continuous decline of TB in the United States since the 185Os, an increase in new TB cases was observed in 1985.
A J, Vartanian, A, Alvi
openaire   +2 more sources

Multidrug-resistant tuberculosis

Infectious Disease Clinics of North America, 2002
Multidrug-resistant TB is a growing public health problem. Although control of the multidrug-resistant TB epidemic has been achieved in New York City, strains of multidrug-resistant TB are found in nearly every state. Much of the world faces a growing problem with no immediate solution.
openaire   +2 more sources